OBJECTIVES Endocrine therapy reduces recurrence risk by 30% to 50% in estrogen receptor (ER)-positive breast cancer. The ER-positive threshold recommended by the American Society of Clinical Oncology/College of American Pathologists is 1% based on studies using the ER-6F11 antibody. ER-SP1 antibody has a higher sensitivity and is more widely used. METHODS We report interobserver concordance m...

Nuclei classification is a mandatory process to obtain scoring information for whole slide images. In immunohistochemistry (IHC) staining specifically estrogen-receptor (ER) biomarker, an Allred score based on the proportion and intensity of cancer nuclear widely used in histopathology practice predict response hormonal treatment. This manually exhaustive can be accelerated with help computatio...

Introduction: Studies of object perception are hampered by the difficulty of mathematically describing the similarity of realistic images. Recently, color based metrics have been developed to search for similar images in large databases of realistic images. Such metrics have been shown to predict human subjects’ similarity rankings of realistic images, because the color of realistic images ofte...

Ki67 is a commonly used marker of cancer cell proliferation, and has significant prognostic value in breast cancer. In spite of its clinical importance, assessment of Ki67 remains a challenge, as current manual scoring methods have high inter- and intra-user variability. A major reason for this variability is selection bias, in that different observers will score different regions of the same t...

Thank you for your interest and comments on our article entitled “Expression of glucagon-like peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance,” which was published in Endocrinology and Metabolism [1]. We reported the expression of the glucagon-like peptide-1 receptor (GLP-1R) in papillary thyroid carcinoma (PTC) tissues based on immunohistochemical (IHC)...